Home » An immune defense drug effective against depression and bipolar disorder: how it works

An immune defense drug effective against depression and bipolar disorder: how it works

by admin
An immune defense drug effective against depression and bipolar disorder: how it works

Italian Researchers Discover Potential New Treatment for Depression and Bipolar Disorder

In a groundbreaking study, Italian researchers have found that Aldesleukin, a synthetic form of the cytokine interleukin 2, has the potential to enhance the effectiveness of therapy against depression and bipolar disorder. The study, conducted by a team of scientists from the Vita – Salute San Raffaele University of Milan and the IRCCS San Raffaele Hospital, has shed light on the role of immunoinflammatory mechanisms in mental health conditions.

The researchers, led by Professor Francesco Benedetti and Doctor Sara Poletti, conducted a Phase 2 study involving 36 patients suffering from either major depressive disorder or bipolar disorder. The results showed that Aldesleukin significantly enhanced the antidepressant response to ongoing SSRI/SNRI treatment in both diagnostic groups and expanded the population of regulatory T immune cells. Furthermore, the study found that the changes in cell frequencies induced by Aldesleukin were predictive of subsequent improvement in the severity of depression.

“This is the first randomized control trial to support the hypothesis that treatment to strengthen the immune system, and in particular T cells, may be an effective way to correct immune-inflammatory abnormalities associated with mood disorders and enhance the antidepressant response,” stated Dr. Poletti. The researchers also noted that no serious adverse reactions were detected in the two diagnostic groups, suggesting that Aldesleukin could be a safe and effective treatment option for individuals with treatment-resistant depression.

The findings of this study have the potential to revolutionize the treatment of depression and bipolar disorder, offering a new avenue for intervention in patients who do not respond to traditional pharmacological therapies. The research, titled “Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers,” was published in the scientific journal Brain, Behavior, and Immunity.

See also  Book S and Electric Scooter Pro among the novelties of Xiaomi for summer 2022

With further research and clinical trials, Aldesleukin could soon become a valuable tool in the fight against mental health conditions, offering hope to millions of individuals around the world who struggle with depression and bipolar disorder.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy